Benzinga | May 10, 2021 04:16PM EDT

Cara Therapeutics Q1 EPS $(0.47) Beats $(0.59) Estimate, Sales $1.935M Miss $2.36M Estimate

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.59) by 20.34 percent. This is a 24.19 percent increase over losses of $(0.62) per share from the same period last year.